IRIDEX/$IRIX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX
About IRIDEX
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
Ticker
$IRIX
Sector
Primary listing
Industry
Health Care Equipment & Supplies
Headquarters
Employees
93
ISIN
US4626841013
Website
IRIDEX Metrics
BasicAdvanced
$16M
-
-$0.43
0.70
-
Price and volume
Market cap
$16M
Beta
0.7
52-week high
$1.45
52-week low
$0.78
Average daily volume
70K
Financial strength
Current ratio
1.949
Quick ratio
1.113
Long term debt to equity
60.989
Total debt to equity
77.335
Profitability
EBITDA (TTM)
-4.938
Gross margin (TTM)
41.18%
Net profit margin (TTM)
-14.61%
Operating margin (TTM)
-10.68%
Effective tax rate (TTM)
-0.59%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
-9.54%
Return on equity (TTM)
-106.93%
Valuation
Price to revenue (TTM)
0.316
Price to book
18.33
Price to tangible book (TTM)
-11.69
Price to free cash flow (TTM)
-2.262
Free cash flow yield (TTM)
-44.21%
Free cash flow per share (TTM)
-41.11%
Growth
Revenue change (TTM)
-2.24%
Earnings per share change (TTM)
-36.23%
3-year revenue growth (CAGR)
-4.10%
10-year revenue growth (CAGR)
1.21%
3-year earnings per share growth (CAGR)
6.64%
10-year earnings per share growth (CAGR)
-7.58%
IRIDEX News
AllArticlesVideos
Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema
GlobeNewsWire·2 weeks ago
Iridex to Report First Quarter 2025 Financial Results on May 13, 2025
GlobeNewsWire·2 months ago
Iridex to Host Strategic Vision Call on April 16, 2025
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for IRIDEX stock?
IRIDEX (IRIX) has a market cap of $16M as of July 04, 2025.
What is the P/E ratio for IRIDEX stock?
The price to earnings (P/E) ratio for IRIDEX (IRIX) stock is 0 as of July 04, 2025.
Does IRIDEX stock pay dividends?
No, IRIDEX (IRIX) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next IRIDEX dividend payment date?
IRIDEX (IRIX) stock does not pay dividends to its shareholders.
What is the beta indicator for IRIDEX?
IRIDEX (IRIX) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.